Researchers borrow from AIDS playbook to tackle rheumatic heart disease

January 22, 2018 by Ansley Gogol, Case Western Reserve University

Billions of US taxpayer dollars have been invested in Africa over the past 15 years to improve care for millions suffering from the HIV/AIDS epidemic; yet health systems on the continent continue to struggle. What if the investments and lessons learned from HIV could be used to improve care for those with other serious chronic conditions?

With this question in mind, researchers from Case Western Reserve University School of Medicine and University Hospitals Cleveland Medical Center, along with investigators and clinicians based in Uganda, borrowed an HIV/AIDS innovation to seek inroads against rheumatic in sub-Saharan Africa.

Usually beginning as strep throat, if untreated, rheumatic heart disease can result in severe heart damage, even death. Monthly, long-term penicillin shots usually slow down its progression and reduce mortality. While largely eliminated in developed countries, rheumatic heart disease leads to over 320,000 deaths each year in Africa, the Middle East, Central and South Asia, and the South Pacific.

The borrowed tool, the HIV treatment-cascade, features a series of distinct, sequential steps for assessing supplied care. The Case Western-led team recently published a study of 1,500-plus patients in Circulation: Cardiovascular Quality and Outcome describing its use in combating rheumatic heart disease, one of the earliest attempts to adapt the model for another serious illness.

A central premise of the cascade is that if medical sites are broadly available and not confined to one location—usually a big city—patients will be more likely to comply with the demanding requirements that treatment can entail, whether taking several medications daily, as with AIDS, or tolerating recurrent needle injections, as with rheumatic heart disease.

In line with this premise, a chief finding of the new study is that difficulty getting to and from care was a more significant barrier to patient progress than either obtaining prescriptions for penicillin injections or patient-adherence to the monthly shot schedule. Of the 82 percent of patients who remained alive during the study, only 57 percent stayed in care for at least a year. But of those, more than 90 percent came for their shots at least nine months of the year. As expected, a key reason patients opted out of care was physical distance from a treatment center. But the researchers also found that for every kilometer closer they were to a health center, patients were six percent more likely to continue in care. Younger patient age and latent, as opposed to active disease status, were also strong independent predictors of patient retention and optimal adherence to care requirements.

"Patients in poorer nations who develop a chronic disease, whether it's AIDS, diabetes, or rheumatic heart disease, face similar obstacles to care," said the study's lead author, Chris Longenecker, MD, assistant professor of medicine at Case Western Reserve University School of Medicine. "We wanted to use the lessons learned in improving AIDS care to do the same for people living with rheumatic heart disease. As was true for people living with HIV in the early days, those living with rheumatic heart disease often have to come to the capital of Uganda, Kampala, for treatment. This means an expensive, five-to-six hour bus ride, assuming they even have the money to pay the fare. There are also the problems of poor roads, limited literacy, and bad weather during rainy season. But beginning in 2003, people living with HIV could get their treatments in health centers more widely dispersed throughout Uganda. We adopted this approach to help address rheumatic heart disease and our study confirms that it is effective. The message is clear: We need to take services to the people."

The ground work for the study was laid in 2012 when RHD Action Uganda, a collaboration of Case Western Reserve University School of Medicine, Children's National Medical Center (Washington, DC), and Makerere University, Uganda Heart Institute, Joint Clinical Research Center, Mbarara University of Science and Technology, and Gulu University School of Medicine—all from Uganda—was established with funding from the Medtronic Foundation. The program works to expand access to rheumatic heart disease care throughout the country. Core components include integrating rheumatic heart disease services into existing HIV/AIDS clinics and primary health care centers, establishing new regional care centers (four to date), training local health workers to deliver rheumatic heart disease services, and developing a national registry, which now keeps track of over 1,800 patients.

Because the new analysis adjusted for distance to the nearest health center, improved retention at regional sites is also likely attributable to more staff, funding, and ancillary resources per capita dedicated to tracking —resulting from the decision to decentralize care. Said Longenecker, "By offering care at the HIV/AIDS clinics, and establishing new care sites, we were able to dramatically increase care options for people living with RHD throughout the country. If efforts such as ours can be expanded throughout Africa, and low-income countries elsewhere, can become a thing of the past in those places, as it has throughout the western world."

Explore further: Death rates from rheumatic heart disease falling since 1990

More information: Chris T. Longenecker et al, Rheumatic Heart Disease Treatment Cascade in Uganda, Circulation: Cardiovascular Quality and Outcomes (2017). DOI: 10.1161/CIRCOUTCOMES.117.004037

Related Stories

Death rates from rheumatic heart disease falling since 1990

August 23, 2017
The risk of dying from rheumatic heart disease, a condition of damaged heart valves caused by bacterial infection that leads to rheumatic fever, has dropped around the world over the last 25 years, according to a new scientific ...

Researchers uncover obstacles that prevent people with RHD in Uganda from receiving life-saving penicillin

April 1, 2015
Penicillin has nearly eradicated rheumatic heart disease (RHD) in the United States. But 15 million people still suffer with the disease worldwide, and 1.4 million die each year, according to World Heart Federation.

Study examines prevalence of rheumatic heart disease in developing country

March 2, 2016
Thomas Pilgrim, M.D., of Bern University Hospital, Bern, Switzerland, and colleagues conducted a study to determine the prevalence and incidence of clinically silent and manifest rheumatic heart disease in Eastern Nepal. ...

Test reveals widespread heart disease among children  

April 28, 2014
An investigation into the prevalence of rheumatic heart disease in Fiji using echocardiography – ultrasound of the heart – has found that many local schoolchildren have rheumatic heart disease of a mild severity, which ...

Innovative software improves chronic rheumatic disease care

December 10, 2014
(HealthDay)—For patients with chronic rheumatic disease, innovative software that aggregates, stores, and displays information can improve quality of care, according to research published online Nov. 24 in Arthritis Care ...

Antibody genes influence forgotten heart disease

May 12, 2017
New research has found that genetic differences in antibody genes alter individuals' susceptibility to rheumatic heart disease, a forgotten inflammatory heart condition – known as 'RHD' – that is rife in developing countries.

Recommended for you

Genetic analysis links obesity with diabetes, coronary artery disease

November 16, 2018
A Cleveland Clinic genetic analysis has found that obesity itself, not just the adverse health effects associated with it, significantly increases the risk of Type 2 diabetes and coronary artery disease. The paper was published ...

Non-coding genetic variant could improve key vascular functions

November 15, 2018
Atherosclerotic disease, the slow and silent hardening and narrowing of the arteries, is a leading cause of mortality worldwide. It is responsible for more than 15 million deaths each year, including an estimated 610,000 ...

Study of two tribes sheds light on role of Western-influenced diet in blood pressure

November 14, 2018
A South American tribe living in near-total isolation with no Western dietary influences showed no increase in average blood pressure from age one to age 60, according to a study led by researchers at Johns Hopkins Bloomberg ...

Heart failure patients shouldn't stop meds even if condition improves: study

November 13, 2018
(HealthDay)—There's bad news for heart failure patients with dilated cardiomyopathy who'd like to stop taking their meds.

Bypass beats stents for diabetics with heart trouble: study

November 13, 2018
(HealthDay)—People with both diabetes and multiple clogged heart arteries live longer if they undergo bypass surgery rather than have their blood vessels reopened with stents, according to follow-up results from a landmark ...

New treatment significantly reduces cardiovascular events when combined with statins

November 12, 2018
Statins are the most commonly used treatment for cardiovascular disease. Despite reducing certain risk factors, if triglyceride levels remain high with use of statins, there is still a significant risk for heart attack, stroke ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.